Research Studies - Blood Sugar Control

  1. "Once-A-Week GLP-1 Analog Studies"

    (Study coordinator: Maria Nardicchio)

    These research studies are for overweight patients with type 2 diabetes who take only one or two oral medications for sugar control and whose A1C result is above 7.0 %. All of these studies involve once a week injection of GLP-1 analogs (similar idea as Byetta or Victoza) which might help with diabetes management and weight loss. All tests, diabetes supplies and oral medications will be provided at no cost to participants.

  2. Medication which lowers sugar by increasing its secretion by the kidneys
    (Study coordinators: Maria Nardicchio, Delaine Douglas)

  3. "ACCORD Trial"

    Type 2 diabetes is a condition that is closely linked to obesity and places people who have the disease at greater risk of cardiovascular disease (CVD). People with type 2 diabetes die of CVD at rates 2 to 4 times higher than those who do not have diabetes. They also experience more nonfatal heart attacks and strokes.
    Grunberger Diabetes Institute is one of 70 clinics in the United States and Canada taking part in a major study that is testing three approaches to lower the risk of heart disease and stroke in adults with type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). ACCORD was testing the effects of intensive glucose control, treatment to increase HDL ("good")-cholesterol and lower triglycerides, and of intensive blood pressure control on major CVD events .
    10,251 participants have enrolled. The trial portion of ACCORD finished on June 30, 2009. Several years of observational follow-up studies will continue for those enrolled. More information about the ACCORD study can be found on the web at www.accordtrial.org.